This article provides a comprehensive overview of master protocol designs, a transformative approach for simultaneously evaluating multiple investigational drugs and/or cancer types within a single trial framework.
This article provides a comprehensive comparative analysis of Patient-Derived Xenograft (PDX) and Patient-Derived Organoid (PDO) models, two transformative technologies in preclinical oncology research.
The validation of reliable cancer stem cell (CSC) biomarkers is a critical frontier in oncology, holding the potential to revolutionize cancer diagnosis, prognosis, and therapeutic development.
Multi-gene signature assays are transforming precision medicine by providing crucial prognostic and predictive insights in oncology and complex diseases.
This article provides a systematic comparison of Immunohistochemistry (IHC) and Next-Generation Sequencing (NGS) for biomarker testing in oncology research and drug development.
This article provides a systematic guide for researchers, scientists, and drug development professionals on evaluating the clinical utility of prognostic and predictive biomarkers.
This article provides a comprehensive guide for researchers and drug development professionals on the critical process of validating machine learning (ML) models for cancer detection.
Organoid technology has revolutionized biomedical research by providing physiologically relevant in vitro models.
This article provides a comprehensive comparative analysis of computational models for predicting anticancer drug sensitivity from genomic data.
This article provides a detailed comparison of umbrella and basket trial designs, two innovative master protocol frameworks revolutionizing oncology drug development.